Article Text

PDF
Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation
  1. Takayuki Baba,
  2. Mariko Kubota-Taniai,
  3. Masayasu Kitahashi,
  4. Kyoko Okada,
  5. Yoshinori Mitamura,
  6. Shuichi Yamamoto
  1. Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  1. Correspondence to Dr Takayuki Baba, Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan; babatakayuki{at}nifty.com

Abstract

Aim To compare the long-term outcome of photodynamic therapy (PDT) with that of intravitreal bevacizumab (IVB) for myopic choroidal neovascularisations (mCNVs).

Methods 24 eyes were selected from 40 consecutive patients with mCNV, and the patients were divided into Group A, consisting of 12 eyes treated by PDT, and Group B, consisting of 12 eyes treated by 1.25 mg IVB. The age and best-corrected visual acuity (BCVA) were matched between the two groups. The BCVA, size of the chorioretinal atrophy surrounding the CNV (CRA), central foveal thickness (CFT) and CNV thickness were determined before and at 12 and 24 months after the treatment.

Results The BCVA did not change after PDT but was significantly improved from 0.75±0.25 to 0.49±0.42 logMAR units at 12 months and to 0.50±0.38 logMAR units at 24 months after IVB. The CFT were significantly reduced in both groups at 12 and 24 months. The CRAs were larger in group A than in group B at 12 and 24 months, and their sizes were correlated with the BCVA.

Conclusion At 24 months, IVB is more effective than PDT in treating mCNV. The enlargement of the CRA might be related to the incomplete visual recovery after PDT.

  • Intravitreal bevacizumab
  • myopic choroidal neovascularisation
  • photodynamic therapy
  • visual recovery
  • choroid
  • macula
  • neovascularisation
  • treatment surgery
  • treatment lasers

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by the Chiba University Graduate School of Medicine, Chiba, Japan.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh